Clinical trials: NMO Spectrum Disorder (NMOSD)
AQP4+ NMOSD
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
The goal of this clinical trial is to find out if the investigational medicine BMS-986353 is safe and well tolerated in adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT07573332
- Testing
- CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Neuromyelitis Optica Spectrum Disorder Attack
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG).
- Trial name
- EASE-NMO (NCT06673394)
- Testing
- Complement protein C5 inhibitor, IVMP
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder
Newly diagnosed NMOSD patients
- Trial name
- NCT07032337
- Volunteers
- 2,985 people
- Sponsor
- Samsung Medical Center
Neuromyelitis Optica Spectrum Disorders (NMOSD)
BLAZE-Limiting Approach in NMOSD
This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651).
- Trial name
- NCT06888622
- Testing
- Eculizumab administration
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Huashan Hospital
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
This is a phase 1b interventional trial of bevacizumab (Avastin®) to evaluate the tolerability/safety and preliminary efficacy of bevacizumab (Avastin®) as add-on therapy for treatment of acute optic neuritis and/or transverse…
- Trial name
- NCT01777412
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
NMO Spectrum Disorder
ACT with NMOSD Patients and Caregivers Pilot Study
This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their…
- Trial name
- NCT05840055
- Testing
- Acceptance and Commitment Therapy
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Neuromyelitis Optica Spectrum Disorders, MOGAD
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in…
- Conditions
- Neuromyelitis Optica Spectrum Disorders, MOGAD, Multiple Sclerosis
- Trial name
- PoGe (NCT06865274)
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
NMOSD is an autoimmune disease of the central nervous system that predominantly affects the spinal cord and optic nerves. The objectives of this study are to assess the efficacy and safety of FcRn antagonists (efgartigmod) for…
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
- Trial name
- FACT (NCT06497374)
- Testing
- Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone
- Volunteers
- 63 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica
Scrambler Trial for Pain in NMOSD
A novel technology called Scrambler Therapy is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of C fibers with the intent of re-organizing maladaptive signaling pathways.
- Trial name
- NCT03452176
- Testing
- Scrambler
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Johns Hopkins University
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
The objectives of this time-to-event study are to assess the efficacy and safety of Daratumumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4)…
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
- Trial name
- DAWN (NCT05403138)
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Tianjin Medical University General Hospital
Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS)
- Trial name
- CAR-AID (NCT06249438)
- Testing
- CD20/BCMA-directed CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- SAkuraSun (NCT05199688)
- Testing
- Satralizumab
- Where
- 14 sites in United States, Argentina and 7 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Neuromyelitis Optica, Devic's Disease
Autologous Transplant To End NMO Spectrum Disorder
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term…
- Conditions
- Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
- Trial name
- ATTEND (NCT03829566)
- Testing
- Rituximab, Cyclophosphamide, Mesna
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Neuromyelitis Optica
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
The aim of this study is to determine whether self-administered, at-home use of a transcutaneous electrical nerve stimulating device is an effective, acceptable and feasible method of relief from neuropathic pain among patients…
- Trial name
- NCT04614454
- Testing
- High Frequency Impulse Therapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.
- Trial name
- TERMINATOR (NCT07699770)
- Testing
- Crisugabalin
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Tang-Du Hospital
Optic Neuritis
Efgartigimod for the Treatment of Acute Optic Neuritis
The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation).
- Trial name
- PET-AON (NCT06453694)
- Testing
- Efgartigimod Alfa
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Anastasia Vishnevetsky, MD, MPH
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
- Trial name
- NCT02200770
- Testing
- Inebilizumab
- Where
- 98 sites in United States, Australia and 23 more
- Volunteers
- 231 people
- Sponsor
- MedImmune LLC
Autoimmune Disease
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory…
- Trial name
- NCT06633042
- Testing
- Universal BCMA-CD19 CART
- Volunteers
- 18 people
- Sponsor
- Bioray Laboratories
Neuromyelitis Optica Spectrum Disorders
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients.
- Trial name
- NCT06697535
- Testing
- JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Neuromyelitis Optica Spectrum Disorder
Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20
CAR-T therapy was proposed and has been recently used for cancer treatment. It has been hailed for its promising remission rates after early stage clinical trials for acute lymphoblastic leukemia.
- Trial name
- NCT03605238
- Testing
- Corticosteroids & tanCART19/20
- Where
- China
- Sponsor
- Chinese PLA General Hospital